Messenger RNA vaccines for cancer immunotherapy: progress promotes promise

Amanda L. Huff; Elizabeth M. Jaffee; Neeha Zaidi

doi:10.1172/JCI156211

Messenger RNA vaccines for cancer immunotherapy: progress promotes promise

Amanda L. Huff, Elizabeth M. Jaffee, Neeha Zaidi

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

The COVID-19 pandemic has elevated mRNA vaccines to global recognition due to their unprecedented success rate in protecting against a deadly virus. This international success is underscored by the remarkable versatility, favorable immunogenicity, and overall safety of the mRNA platform in diverse populations. Although mRNA vaccines have been studied in preclinical models and patients with cancer for almost three decades, development has been slow. The recent technological advances responsible for the COVID-19 vaccines have potential implications for successfully adapting this vaccine platform for cancer therapeutics. Here we discuss the lessons learned along with the chemical, biologic, and immunologic adaptations needed to optimize mRNA technology to successfully treat cancers.

Original language	English (US)
Article number	e156211
Journal	Journal of Clinical Investigation
Volume	132
Issue number	6
DOIs	https://doi.org/10.1172/JCI156211
State	Published - Mar 15 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1172/JCI156211

Cite this

@article{efea6b855c994ef5b5a8ec49d84b1908,

title = "Messenger RNA vaccines for cancer immunotherapy: progress promotes promise",

abstract = "The COVID-19 pandemic has elevated mRNA vaccines to global recognition due to their unprecedented success rate in protecting against a deadly virus. This international success is underscored by the remarkable versatility, favorable immunogenicity, and overall safety of the mRNA platform in diverse populations. Although mRNA vaccines have been studied in preclinical models and patients with cancer for almost three decades, development has been slow. The recent technological advances responsible for the COVID-19 vaccines have potential implications for successfully adapting this vaccine platform for cancer therapeutics. Here we discuss the lessons learned along with the chemical, biologic, and immunologic adaptations needed to optimize mRNA technology to successfully treat cancers.",

author = "Huff, {Amanda L.} and Jaffee, {Elizabeth M.} and Neeha Zaidi",

year = "2022",

month = mar,

day = "15",

doi = "10.1172/JCI156211",

language = "English (US)",

volume = "132",

journal = "Journal of Clinical Investigation",

issn = "0021-9738",

publisher = "The American Society for Clinical Investigation",

number = "6",

}

TY - JOUR

T1 - Messenger RNA vaccines for cancer immunotherapy

T2 - progress promotes promise

AU - Huff, Amanda L.

AU - Jaffee, Elizabeth M.

AU - Zaidi, Neeha

PY - 2022/3/15

Y1 - 2022/3/15

N2 - The COVID-19 pandemic has elevated mRNA vaccines to global recognition due to their unprecedented success rate in protecting against a deadly virus. This international success is underscored by the remarkable versatility, favorable immunogenicity, and overall safety of the mRNA platform in diverse populations. Although mRNA vaccines have been studied in preclinical models and patients with cancer for almost three decades, development has been slow. The recent technological advances responsible for the COVID-19 vaccines have potential implications for successfully adapting this vaccine platform for cancer therapeutics. Here we discuss the lessons learned along with the chemical, biologic, and immunologic adaptations needed to optimize mRNA technology to successfully treat cancers.

AB - The COVID-19 pandemic has elevated mRNA vaccines to global recognition due to their unprecedented success rate in protecting against a deadly virus. This international success is underscored by the remarkable versatility, favorable immunogenicity, and overall safety of the mRNA platform in diverse populations. Although mRNA vaccines have been studied in preclinical models and patients with cancer for almost three decades, development has been slow. The recent technological advances responsible for the COVID-19 vaccines have potential implications for successfully adapting this vaccine platform for cancer therapeutics. Here we discuss the lessons learned along with the chemical, biologic, and immunologic adaptations needed to optimize mRNA technology to successfully treat cancers.

UR - http://www.scopus.com/inward/record.url?scp=85126654143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126654143&partnerID=8YFLogxK

U2 - 10.1172/JCI156211

DO - 10.1172/JCI156211

M3 - Review article

C2 - 35289317

AN - SCOPUS:85126654143

SN - 0021-9738

VL - 132

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

IS - 6

M1 - e156211

ER -

Messenger RNA vaccines for cancer immunotherapy: progress promotes promise

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this